Fig. 2.

Estimated incidences of myocarditis after COVID-19 vaccine administration derived from our data and as reported in the following government registries or studies: UK (Spikevax) = reported incidence of myocarditis (34 per million doses) after Spikevax (Moderna) vaccine administration in the UK (government report) [7]; Israel (Comirnaty) = reported incidence of myocarditis (26.7 per million doses) after Comirnaty (Pfizer-BioNTech) vaccine administration in Israel (observational retrospective study based on Ministry of Health database) [8]; Canada = reported incidence of myocarditis (23.1 per million doses) after COVID-19 vaccine administration in Canada (government report) [9]; UK (Comirnaty) = reported incidence of myocarditis (9 per million doses) after Comirnaty (Pfizer-BioNTech) vaccine administration in the UK (government report) [7]; CDC = reported incidence of myocarditis (8.3 per million doses) after COVID-19 vaccines administration in the USA (CDC report) [2]; current research = estimated incidence (3.4 per million doses) from CMR data reported in the present study